Real-World Adoption of Adjuvant Therapies for Resected Stage IB–III Non-Small-Cell Lung Cancer
Cancers · 10.09.2025 · 17 (18) · 2961
DOI: 10.3390/cancers17182961 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 10.09.2025. Verfasst von Arvind Kumar und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca, NCI NIH HHS, Veterans Health Administration.
Abstract (Originalsprache)
Background
Recent clinical trials support adjuvant treatment with novel immunotherapy and targeted therapy agents for selected non-small-cell lung cancer (NSCLC) after resection. The “real-world” implementation of these treatments, however, remains unknown. This study evaluated trends in the uptake of adjuvant chemotherapy, immunotherapy, and targeted therapy for patients with resected NSCLC.
Methods
Patients with resected stage IB-III NSCLC within the Veterans Health Administration (2017−2023) were included. Use of adjuvant chemotherapy, immunotherapy, and/or targeted therapy was evaluated over the study period. Factors associated with adjuvant therapy use were identified using multivariable-adjusted logistic regression.
Results
Of the 1980 patients included, 846 (42.7%) underwent adjuvant therapy. There was a modest but not statistically significant increase in adjuvant therapy use from 37.1% in 2017 to 45.9% in 2023. Use of adjuvant chemotherapy alone declined from 36.6% to 23.5%, while use of adjuvant immunotherapy (0.5% to 21.2%) and targeted therapy (0% to 1.2%) increased. Factors associated with adjuvant therapy use included younger age, fewer comorbidities, and higher tumor stage.
Conclusions
Despite the increased use of adjuvant immunotherapy and targeted therapy for resected stage IB-III NSCLC, overall adjuvant therapy uptake remains low. Further efforts will be necessary to better incorporate these novel treatments into routine clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.
- Veterans Affairs St. Louis Health Care System, St. Louis, MO 63110, USA.
- Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
- Division of Hematology and Medical Oncology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO 63110, USA.
- Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.
- School of Public Health, Washington University in St. Louis, St. Louis, MO 63110, USA.
ORCID-Profile: Arvind Kumar, Steven Tohmasi, Nahom Seyoum, Martin W Schoen, Su-Hsin Chang, Molly C Tokaz, Brendan T Heiden
Förderung
- AstraZeneca
- NCI NIH HHS
- Veterans Health Administration
- HSRD VA
- National Cancer Institute
Zitieren
APA
Kumar, A., Tohmasi, S., Eaton, D. B., Seyoum, N., Brandt, W. S., Thomas, T. S., Schoen, M. W., Rossetti, N. E., Chang, S. H., Yan, Y., Patel, M. R., Malone, S., Tokaz, M. C., Meyers, B. F., Kozower, B. D., Puri, V., & Heiden, B. T. (2025). Real-World Adoption of Adjuvant Therapies for Resected Stage IB–III Non-Small-Cell Lung Cancer. Cancers, 17(18), 2961. https://doi.org/10.3390/cancers17182961
Vancouver
Kumar A, Tohmasi S, Eaton DB, Seyoum N, Brandt WS, Thomas TS, et al. Real-World Adoption of Adjuvant Therapies for Resected Stage IB–III Non-Small-Cell Lung Cancer. Cancers. 2025;17(18):2961. doi:10.3390/cancers17182961
BibTeX
@article{Kumar2025,
author = {Kumar, Arvind and Tohmasi, Steven and Eaton, Daniel B and Seyoum, Nahom and Brandt, Whitney S and Thomas, Theodore S and Schoen, Martin W and Rossetti, Nikki E and Chang, Su-Hsin and Yan, Yan and Patel, Mayank R and Malone, Sara and Tokaz, Molly C and Meyers, Bryan F and Kozower, Benjamin D and Puri, Varun and Heiden, Brendan T},
title = {Real-World Adoption of Adjuvant Therapies for Resected Stage IB–III Non-Small-Cell Lung Cancer},
journal = {Cancers},
year = {2025},
volume = {17},
number = {18},
pages = {2961},
doi = {10.3390/cancers17182961}
}
EUVIMED